investorscraft@gmail.com

Intrinsic Value of Adverum Biotechnologies, Inc. (ADVM)

Previous Close$2.28
Intrinsic Value
Upside potential
Previous Close
$2.28

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2024 and quarterly data as of .

Data is not available at this time.

Stock Valuation Context

Business Model And Market Position

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company focused on developing treatments for ocular and rare diseases. The company leverages its proprietary intravitreal gene therapy platform to deliver durable therapeutic effects with a single administration, targeting conditions such as wet age-related macular degeneration (AMD) and hereditary angioedema. Adverum operates in the highly competitive biopharmaceutical sector, where innovation and clinical validation are critical to securing market share. Its pipeline is designed to address unmet medical needs, positioning it as a potential disruptor in gene therapy. The company’s revenue model relies heavily on strategic partnerships, grants, and future commercialization of its therapies, contingent on successful clinical trials and regulatory approvals. While still in the development phase, Adverum’s focus on novel delivery mechanisms and sustained efficacy differentiates it from traditional treatment approaches. The gene therapy market is rapidly evolving, with increasing investor interest in long-term curative solutions, providing Adverum with opportunities to capitalize on its scientific advancements.

Revenue Profitability And Efficiency

Adverum reported minimal revenue of $1 million, reflecting its pre-commercial stage, while net losses widened to -$130.9 million, driven by R&D expenses. The company’s operating cash flow was -$92.5 million, underscoring its heavy investment in clinical development. Capital expenditures were modest at -$388,000, indicating a lean operational approach focused on advancing its pipeline rather than infrastructure.

Earnings Power And Capital Efficiency

Adverum’s diluted EPS of -$6.62 highlights its current lack of earnings power, typical of clinical-stage biotech firms. The company’s capital efficiency is constrained by high R&D burn rates, with profitability contingent on successful trial outcomes and future commercialization. Its ability to sustain operations depends on securing additional funding or partnerships to bridge the gap to potential revenue generation.

Balance Sheet And Financial Health

Adverum holds $60.7 million in cash and equivalents against $91.7 million in total debt, raising liquidity concerns given its cash burn. The debt load may necessitate further equity raises or refinancing. With no dividend payments, the company prioritizes reinvestment in its pipeline, but its financial health remains fragile without near-term revenue streams.

Growth Trends And Dividend Policy

Adverum’s growth hinges on clinical milestones and regulatory progress, with no dividends issued as it conserves capital. The company’s trajectory depends on advancing its lead candidates through trials and securing partnerships. Investor returns are speculative, tied to long-term therapeutic success rather than current income generation.

Valuation And Market Expectations

The market values Adverum based on its pipeline potential rather than current financials, with volatility reflecting clinical trial risks. Its valuation is sensitive to data readouts and regulatory updates, with investors pricing in binary outcomes for its gene therapy platforms. The absence of near-term revenue amplifies reliance on speculative growth premiums.

Strategic Advantages And Outlook

Adverum’s proprietary gene delivery technology provides a competitive edge, but execution risks remain high. The outlook depends on clinical success, regulatory approvals, and funding stability. While the company is well-positioned in a high-growth sector, its ability to transition from R&D to commercialization will determine its long-term viability.

Sources

Company filings (10-K), investor presentations

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2025202620272028202920302031203220332034203520362037203820392040204120422043204420452046204720482049

INCOME STATEMENT

Revenue growth rate, %NaN
Revenue, $NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $mNaN
Operating income, $mNaN
EBITDA, $mNaN
Interest expense (income), $mNaN
Earnings before tax, $mNaN
Tax expense, $mNaN
Net income, $mNaN

BALANCE SHEET

Cash and short-term investments, $mNaN
Total assets, $mNaN
Adjusted assets (=assets-cash), $mNaN
Average production assets, $mNaN
Working capital, $mNaN
Total debt, $mNaN
Total liabilities, $mNaN
Total equity, $mNaN
Debt-to-equity ratioNaN
Adjusted equity ratioNaN

CASH FLOW

Net income, $mNaN
Depreciation, amort., depletion, $mNaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $mNaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $mNaN
Free cash flow, $mNaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $mNaN
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount